Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
KPC Pharmaceuticals, Inc. (600422.SS)
Kunming, CN
KPC Pharmaceuticals, Inc. operates as a pharmaceutical enterprise, with its operations spanning drug research and development, manufacturing, marketing, and wholesale distribution. The company serves both domestic markets within the People's Republic of China and international clientele. Its portfolio prominently features botanical drugs, including artemether, panax notoginseng, and gastrodine series medications. These, along with various Chinese and ethnic remedies—marketed under brand names such as Luotai, Tianxuanqing, Artemedine, Artem, and Arco—are deployed in the treatment of conditions affecting the cardiovascular and cerebrovascular systems, neurological disorders, and malaria. Beyond its herbal focus, KPC Pharmaceuticals supplies a broad range of healthcare products. These include Dai ethnic preparations, antibiotics, raw chemical materials, prepared chemical pharmaceuticals, traditional Chinese medicinal ingredients, biologicals, biochemical agents, and nutritional supplements. Specific offerings encompass Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, Ribavirin spray, glycyrrhizic acid, and the long-acting hypoglycemic GLP-1. Additionally, the company distributes artemisinin-based antimalarials, various generic medications, and medical devices. Established in 1951, the firm was initially known as Kunming Pharmaceutical Corporation before adopting its current name, KPC Pharmaceuticals, Inc., in April 2015. Its corporate headquarters are located in Kunming, situated in the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.32% | +5.81% | -6.00% | -27.28% | -32.09% | -28.90% | -43.98% | -63.70% | -8.88% | -29.18% | +160.35% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-21.7% Q1'26: -48.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-46.5% Q1'26: -258.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+2.0% Q1'26: -76.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.2% Q1'26: -22.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.3% Q1'26: -10.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.0% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.31× ★ Q1'26: -2.46× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.92B
est: 4.90B (+0.3%)
|
5.10B
est: 4.90B (+4.1%)
|
5.85B
est: 5.29B (+10.7%)
|
7.10B
est: 5.60B (+26.8%)
|
8.12B
est: 6.99B (+16.1%)
|
7.91B
est.
|
7.72B
est: 8.55B (-9.7%)
|
8.25B
est: 8.55B (-3.4%)
|
8.28B
est: 8.57B (-3.3%)
|
8.43B
est: 7.49B (+12.6%)
|
8.40B
est: 8.31B (+1.2%)
|
6.58B
est: 6.96B (-5.5%)
|
6.76B
6.73B – 6.82B
-2.8% YoY
|
7.15B
7.05B – 7.31B
+5.8% YoY
|
7.59B
7.53B – 7.65B
+6.1% YoY
|
| EBITDA |
606.64M
est: 452.08M (+34.2%)
|
588.00M
est: 452.08M (+30.1%)
|
530.37M
est: 487.69M (+8.8%)
|
563.63M
est: 516.85M (+9.1%)
|
711.41M
est: 645.28M (+10.2%)
|
729.79M
est.
|
728.82M
est: 788.65M (-7.6%)
|
831.81M
est: 788.65M (+5.5%)
|
705.23M
est: 790.31M (-10.8%)
|
981.09M
est: 799.02M (+22.8%)
|
1.13B
est: 886.37M (+27.3%)
|
638.22M
est: 742.47M (-14.0%)
|
721.92M
718.33M – 728.31M
-2.8% YoY
|
763.58M
752.65M – 780.63M
+5.8% YoY
|
810.24M
803.73M – 816.75M
+6.1% YoY
|
| EBIT |
529.79M
est: 353.10M (+50.0%)
|
506.98M
est: 353.10M (+43.6%)
|
435.59M
est: 380.92M (+14.4%)
|
463.50M
est: 403.69M (+14.8%)
|
587.91M
est: 504.00M (+16.6%)
|
570.01M
est.
|
577.93M
est: 615.99M (-6.2%)
|
672.95M
est: 615.99M (+9.2%)
|
524.74M
est: 617.28M (-15.0%)
|
805.69M
est: 639.58M (+26.0%)
|
963.32M
est: 709.50M (+35.8%)
|
473.56M
est: 594.31M (-20.3%)
|
577.86M
574.99M – 582.98M
-2.8% YoY
|
611.21M
602.47M – 624.86M
+5.8% YoY
|
648.56M
643.35M – 653.77M
+6.1% YoY
|
| Net Income |
420.85M
est: 395.63M (+6.4%)
|
407.26M
est: 395.63M (+2.9%)
|
330.10M
est: 429.54M (-23.2%)
|
335.54M
est: 331.58M (+1.2%)
|
454.31M
est: 324.04M (+40.2%)
|
422.01M
est.
|
456.86M
est: 482.29M (-5.3%)
|
507.67M
est: 482.29M (+5.3%)
|
383.18M
est: 519.97M (-26.3%)
|
540.71M
est: 458.40M (+18.0%)
|
648.08M
est: 639.34M (+1.4%)
|
349.94M
est: 408.59M (-14.4%)
|
316.58M
205.25M – 327.11M
-22.5% YoY
|
400.00M
318.42M – 447.14M
+26.4% YoY
|
479.89M
368.91M – 539.70M
+20.0% YoY
|
| SGA |
1.16B
est: 1.64B (-29.3%)
|
1.51B
est: 1.64B (-8.4%)
|
2.10B
est: 1.77B (+18.2%)
|
2.98B
est: 1.88B (+58.2%)
|
3.31B
est: 2.35B (+40.9%)
|
2.66B
est.
|
2.65B
est: 2.87B (-7.8%)
|
2.78B
est: 2.87B (-3.2%)
|
2.79B
est: 2.88B (-2.9%)
|
2.98B
est: 2.48B (+20.4%)
|
2.59B
est: 2.75B (-5.7%)
|
2.09B
est: 2.30B (-9.3%)
|
2.24B
2.23B – 2.26B
-2.8% YoY
|
2.37B
2.33B – 2.42B
+5.8% YoY
|
2.51B
2.49B – 2.53B
+6.1% YoY
|
| EPS |
0.53
est: 0.53 (+1.0%)
|
0.52
est: 0.53 (-1.0%)
|
0.42
est: 0.57 (-26.3%)
|
0.44
est: 0.44 (+0.0%)
|
0.60
est: 0.43 (+39.5%)
|
0.56
est.
|
0.60
est: 0.64 (-6.3%)
|
0.67
est: 0.64 (+4.7%)
|
0.51
est: 0.69 (-26.1%)
|
0.71
est: 0.60 (+18.3%)
|
0.86
est: 0.84 (+2.7%)
|
0.46
est: 0.54 (-14.0%)
|
0.35
0.27 – 0.43
-34.2% YoY
|
0.47
0.42 – 0.59
+34.1% YoY
|
0.57
0.48 – 0.71
+20.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 229.9K | 0.06% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 64.5K | 0.29% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 17.6K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 7.8K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 868.5K | 0.06% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 23.2K | 0.28% |
| 7 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.02M | 0.05% |
| 8 | Vanguard ESG International Stock ETF VSGX | 0.00% | 8.3K | 0.10% |
| 9 | Vanguard Total World Stock ETF VT | 0.00% | 54.5K | 0.06% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.4K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cheng Sun | Vice President | — | male |
| Jiang Zhong | President | — | male |
| JunFeng Liu | Senior Vice President | — | male |
| Kai Xi | Vice President | — | male |
| Lei Sun | Head of Accounting Department | — | male |
| Li Chun Li | Vice President | — | male |
| Li Meng | Executive Vice President | — | female |
| Mengxun Zhang | VP, Board Secretary & General Counsel | — | female |
| Sun Zhi Qiang | Financial Director | — | male |
| Tong Gao | Vice President | — | male |
| Wei Yan | President & Vice Chairman | — | male |
| Zhang Mengxun | Board Secretary & General Counsel | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600422.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
